The correction of genetic mutations by homologous recombination is an attractive approach to gene therapy. We used the DNA double-strand breaks introduced by the site-specific endonuclease I-Sce1 as a means of increasing homologous recombination of an exogenous DNA template in murine hematopoietic stem cells (mHSCs). To develop this approach, we chose an Artemis knockout (Art phenotype in 2 of our 10 experiments. Even though the potential for genotoxicity has yet to be evaluated, this new approach to gene editing appears to be promising. Improving the efficacy of this approach will require further technical work.
INTRODUCTION
The feasibility and efficacy of gene therapy based on gamma retroviruses has been demonstrated in two forms of severe combined immunodeficiency (SCID): X-linked SCID and adenosine deaminase deficiency. 1 However, the occurrence of severe adverse events in some patients prompted researchers to consider new approaches, such as gene editing by homologous recombination (HR). 2, 3 The major advantages of HR are controlled endogenous expression and a strong decrease in the risk of insertional mutagenesis (relative to previous retrovirus-based gene therapy protocols). In contrast to embryonic cells, adult primary cells use this error-free repair mechanism less frequently than the errorprone non-homologous end joining pathway. 4 However, the frequency of HR in adult primary cells can be increased by introducing double-strand breaks and a DNA template. 5 To assess the feasibility of this approach, we chose to study an Artemis knockout mouse model (Art
, created by replacement of Artemis exon 12 by a restriction site for I-Sce1 meganuclease). 6 
Art
− / − mice exhibit (i) early T-and B-cell maturation arrest (caused by a V(D)J recombination defect) and (ii) increased sensitivity to ionizing radiation; this mimics the T-B-NK + SCIDs observed in humans. 7 In the context of this radiosensitive SCID, corrected cells are expected to have a large selective advantage-as was first shown for the gene therapy of SCID-X1. 8 Although previous work on a variety of cells has demonstrated the feasibility of HR-based gene correction using zinc-finger nucleases, 9-11 harmful off-target effects are unacceptably frequent after zinc-finger nuclease transduction. 12, 13 In the present study, we attempted to correct Art − / − murine hematopoietic stem cells (mHSCs) by using I-Sce1-meganuclease-induced HR and an Artemis matrix. The I-Sce1 meganuclease was delivered by a self-inactivating (SIN)-integrasedefective lentiviral vector (SIN-IDLV) (Figure 1a ) that enabled transient gene expression through the dilution of the nonintegrated, episomal forms of the vector during the proliferation of transduced cells. The Artemis correction template was also delivered by a SIN-IDLV (Figure 1b) . In the absence of promoter, it provides a non-integrating DNA template for HR. We evidenced successful gene targeting in this particular model by monitoring reversion of the Artemis phenotype in a number of assays (including in vitro T-cell development assays and genomic analyses).
RESULTS AND DISCUSSION
The sensitivity of HR detection To ensure that we were able to detect low numbers of HR events, we evaluated the sensitivity of our HR detection assays. We first explored the PCR's sensitivity by diluting wild-type (WT) genomic DNA (gDNA) in Art − / − gDNA (thus mimicking HR repair). The PCRs were performed with a range of 10 fg to 100 ng of WT gDNA completed to 100 ng with Art − / − gDNA. As shown in Figure 2b , the HR band (1200 bp) was detectable when 10 pg of gDNA was used; this roughly corresponds to three genome-repaired cells. Next, we explored the sensitivity of the in vitro T-cell differentiation assay by diluting Sca1 + cells (derived from WT mice) with Art − / − Sca1 + cells ( Figure 2c ). As previously described, 6 the Art − / − mice showed a thymic T-cell development arrest at the double-negative 3 progenitor stage (CD44 − /CD25 + ). We therefore used T-cell differentiation to demonstrate reversion of this blockage. After 21 days of culture, we found that 100-1000 WT 1 cells were needed to restore T-cell differentiation characterized by CD4 + /CD8 + double-positive (DP) cells and CD3 + /TCRgd + cells. We further confirmed this result in a limiting dilution assay. Briefly, several doses of WT Sca1 + cells (15-1000 cells) were plated for 21 days on murine OP9DL1 (mOP9DL1) stroma cells. We established the T-cell precursor frequency using 24 wells per condition. Each well was analyzed for CD3, CD4, CD8 and TCRgd markers using fluorescence-activated cell sorting . The T-cell precursor frequency (corresponding to the condition in which 37% of the wells were negative for these markers) was 1 in 1632-far lower than our previously obtained values (Figure 2d ). We performed another limiting dilution assay in which the same quantity of Art − / − cells was mixed with WT cells (in order to obtain a total of 10 000 cells) and found a frequency of 1 in 658. We hypothesize that this difference might be due to mutual stimulation of mHSCs via secreted factors or cell-cell interactions. We concluded that at least 658 repaired cells are required for the detection of in vitro T-cell differentiation. Hence, the nested-PCR and T-cell differentiation assays were able to detect HR events in at least 0.01% and 1.3% of the target cells, respectively.
Correction of Art
− / − Sca1 + cells by HR
We detected reversion of the Art -/-phenotype in transduced Sca1 + cells in 2 of the 10 independent in vitro T-cell differentiation assays, with passage through the double-negative (DN) 3 stage after 36 and 32 days of co-culture, respectively. In the first experiment (Figure 3a) , 16 .6% of the cells were DN4 and 2.04% were DP. In the second experiment, 2.74% of the cells were DN4 and 1.95% were DP. The first experiment generated enough cells to perform a PCR on gDNA, and the observation of a 1200-bp band revealed the presence of HR events (Figure 3b ). In parallel with the T-cell differentiation assays, we also performed PCR assays on Sca1 + gDNA 1 week after transduction (that is, in the absence of T-cell differentiation). The PCR was positive in 2 of 10 independent experiments (Figure 3c ). Taken as a whole, our results show that the low observed number of HR events was indeed due to the low frequency of HR in mHSCs, rather than poor assay sensitivity. Although we had hoped to see a selective advantage of repaired cells in vivo, the low frequency of HR and the leakiness of some Art − / − mice prevented us from starting in vivo experiments before having obtained higher rates. The literature data in this field indicate that the efficiency of HR-mediated gene correction varied significantly among the different cell types, with hematopoietic progenitors showing the lowest efficiency. One rate-limiting factor may be the permissiveness of the target cell to multiple LV infection, known to be much lower in hematopoietic stem cells than in immortalized cells.
14 HR approach will also require a tight safety assessment, including any potential off-targets. 11 This includes determining the number and location of I-Sce1-induced double-strand breaks in target cells by high-throughput sequencing and evaluating the long-term repopulation and differentiation potential of I-Sce1-treated cells. Work on overcoming the low efficiency and off-target effects is now in progress. Paulk et al. 15 used drugs to prevent nonhomologous end joining from correcting double-strand breaks, and recent advances in nuclease engineering for zinc-finger nucleases, transcription activator-like effector nuclease and clustered regulatory interspaced short palindromic repeat (CRISPR)/Cas promise to enhance the safety and efficacy of targeted genetic alterations in the future. 16 Nevertheless, we confirmed here the occurrence of gene editing in primary mHSCs. We are now focusing our efforts on significantly improving our technique's efficacy, with a view to offering low-risk in vivo correction of this life-threatening primary immune disorder.
MATERIALS AND METHODS

Artemis knockout mice
Art − / − mice were produced as described previously 17 and were maintained in specific-pathogen-free conditions. All experiments and procedures were performed in compliance with the French Ministry of 
Lentiviral vector construction, production and titration
The SIN-IDLV-CMV-ISce1, SIN-IDLV-Art, SIN-LV-PGK-Art and SIN-LV-PGK-GFP vectors were all developed using the pTrip backbone. SIN-LV-PGK-Artemis and SIN-LV-PGK-GFP were used as control 'integrating' vector counterparts. High-titer stocks of these vectors were produced by transient tripartite calcium phosphate transfection of 293T cells with (i) the vector plasmid, (ii) an encapsidation plasmid encoding a mutated integrase (D64V) 18 or the native HIV integrase 19 and (iii) a vesicular stomatitis virus envelope (VSV-g) 20 plasmid. The supernatants were concentrated by ultracentifugation as described previously. 21 The vector titer was determined by quantitative PCR.
Isolation, transduction and T-cell differentiation of mHSCs Murine HSCs were purified and transduced as described previously. 6 Briefly, Art − / −-mice were killed at the age of 4-8 weeks. Sca1 + cells were sorted by magnetic selection and cultured in a cytokine cocktail (100 ng ml − 1 of mSCF, mFlt3L, mTPO and mIL11 and 50 ng ml − 1 of mIL6, PeproTech, Rocky Hill, NJ, USA) for between 4 and 48 h. Next, between 200 000 and 250 000 cells were transduced with lentiviral vector at a multiplicity of infection of 50. At 24 or 48 h after transduction, the cells were cultured for in vitro T-cell differentiation on mOP9DL1 stroma cells in the presence of 5 ng ml − 1 of mFlt3L and 2 ng ml − 1 of mIL7. 22 Each week, a sample of the cultured cells was stained for CD44/CD25/CD4/CD8 markers.
PCR for genomic DNA
To test genome repair by HR, we developed a semi-nested PCR that was able to discriminate between the Artemis loci in Art − / − and the corrected gDNA (Figure 2a ). Different amounts of WT gDNA (100, 10, 1, 0.1, 0.01, 0.001, 0.0001 ng) were mixed with Art − / − gDNA to obtain 100 ng of gDNA in total. The first PCR used two primers (one in the genomic region and the other in the left homology arm of the correction template), in order to avoid detection of residual episomal template (1: 5′-ATGGTTAAA TCTAGTTCCCACC-3′, 3: 5′-TTAACTCTTGCCTTGCTAGCC-3′). The second PCR used two primers located in the homologous regions (1 and 2: 5′-AGTCTTCCTCAGTCTCAGG-3′). All the PCRs were performed under standard condition.
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